Metocor (Metoprolol)

Metoprolol blocks β1‑adrenergic receptors in the heart, diminishing the effects of adrenaline and noradrenaline. This leads to a slower heart rate, reduced contractile force, and lower cardiac output, which together lower blood pressure and myocardial oxygen demand, providing therapeutic benefit in cardiovascular disease.

The specific dose of Metocor is determined by the prescribing clinician based on the patient’s condition, age, renal function, and response to therapy. Dosage regimens vary widely, and the prescriber will tailor the amount and frequency to achieve optimal clinical outcomes.

Safety data for metoprolol in pregnancy are limited, and the drug is generally classified as use‑only if the potential benefit justifies the risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the Metocor product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metocor (metoprolol) is a cardio‑selective β1‑blocker, offering a lower risk of bronchospasm compared with non‑selective agents like propranolol. Its pharmacokinetic profile provides once‑ or twice‑daily dosing, and it is widely used for heart‑failure management, whereas some alternatives may be preferred for migraine prophylaxis or tremor control.

Metocor tablets should be stored at temperatures below 25 °C, in a dry place, and kept in the original container to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Metocor is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a full glass of water. The dosing schedule (once or twice daily) depends on the clinical indication and individual patient response.

Serious adverse events include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with reactive airway disease, and worsening heart failure. Patients should be monitored for signs of these conditions, especially during dose initiation or adjustment.

Metocor is contraindicated in patients with known hypersensitivity to metoprolol or other beta‑blockers, those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, cardiogenic shock, and uncontrolled severe asthma or COPD. Clinicians should assess each patient’s medical history before prescribing.